Article Dans Une Revue Rheumatology Année : 2025

E094 BASDAI and ASDAS disease states in relationship to ASAS40 response: post hoc analysis from the ixekizumab COAST-V study in radiographic axial spondyloarthritis

Résumé

Background/Aims To explore the relationship between Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Ankylosing Disease Activity Score (ASDAS) used in clinical practice and the Assessment of SpondyloArthritis international Society 40% (ASAS40) response, the primary endpoint in clinical trials in axial spondyloarthritis (axSpA). Methods Data from COAST-V, a phase 3 trial of ixekizumab versus placebo in biologic-naïve radiographic axSpA (r-axSpA) patients, were analysed. Patients treated with ixekizumab every 4 weeks were categorized using ASAS40 response at week 16 (48.1%; 39/81) and 52 (53.1%; 43/81). The association between BASDAI and ASDAS disease states, respectively, and ASAS40 response achieved/not achieved was investigated. Additionally, back pain, fatigue, Bath Ankylosing Spondylitis Functional Index, ASAS Health Index, and 36-item Short Form Health Survey Physical Component Summary scores corresponding to these states were assessed. Results were reported descriptively. Results After 16 weeks, 71.8% (n = 28) and 43.6% (n = 17) patients achieved BASDAI<3 and BASDAI<2, respectively; 76.9% (n = 30) and 33.3% (n = 13) attained ASDAS<2.1 and ASDAS<1.3, respectively, among those who achieved an ASAS40 response. At week 52, 83.8% (n = 36) and 51.2% (n = 22) patients achieved BASDAI<3 and BASDAI<2, respectively; 93.1% (n = 40) and 41.9% (n = 18) attained ASDAS<2.1 and ASDAS<1.3, respectively, among ASAS40 responders. Lower BASDAI and ASDAS disease states corresponded well with less back pain, fatigue, and functioning impairment, and better health-related quality of life (Table 1). Conclusion When analysing the common clinical practice tools BASDAI and ASDAS, low disease activity or inactive disease were attained in more than 70% of biologic-naïve r-axSpA patients who achieved an ASAS40 response in a randomized clinical trial. This data may further help to translate results from clinical trials into daily practice. Disclosure M. Rudwaleit: Consultancies; Abbvie, Boehringer-Ingelheim, Eli Lilly, Janssen, Novartis, UCB. V. Navarro Compán: Consultancies; AbbVie, Eli Lilly, Galapagos, Moonlake, MSD, Novartis, Pfizer, and UCB Pharma. Member of speakers’ bureau; AbbVie, Eli Lilly, Fresenius Kabi, Janssen, MSD, Novartis, Pfizer, and UCB Pharma. Grants/research support; AbbVie and Novartis. H. Russ: Corporate appointments; Eli Lilly and Company. Shareholder/stock ownership; Eli Lilly and Company. T. Panni: Corporate appointments; Eli Lilly and Company. Shareholder/stock ownership; Eli Lilly and Company. E. Filippi: Corporate appointments; Eli Lilly and Company. Shareholder/stock ownership; Eli Lilly and Company. M. Nassab: Corporate appointments; Eli Lilly and Company. Shareholder/stock ownership; Eli Lilly and Company. S. Liu-Leage: Corporate appointments; Eli Lilly and Company. Shareholder/stock ownership; Eli Lilly and Company. V. Goëb: Consultancies; Abbvie, Galapagos, Janssen, Medac, MSD, Pfizer, Eli Lilly. F. Ciccia: Consultancies; Abbvie, Astra-Zeneca, Bristol-Myers Squibb, Celgene, Eli Lilly and Company, GSK, Janssen, Novartis, Pfizer, Sanofi-Aventis, and UCB Pharma. Grants/research support; Abbvie, Astra-Zeneca, Bristol-Myers Squibb, Celgene, Eli Lilly and Company, GSK, Janssen, Novartis, Pfizer, Sanofi-Aventis, and UCB Pharma. J. Dudler: Consultancies; AbbVie, GSK, Janssen, Novartis, Eli Lilly and Company. M. Todd: Corporate appointments; Eli Lilly and Company. Shareholder/stock ownership; Eli Lilly and Company.

Fichier non déposé

Dates et versions

hal-05107335 , version 1 (11-06-2025)

Identifiants

Citer

Martin Rudwaleit, Victoria Navarro Compán, Hagen Russ, Tommaso Panni, Erica Filippi, et al.. E094 BASDAI and ASDAS disease states in relationship to ASAS40 response: post hoc analysis from the ixekizumab COAST-V study in radiographic axial spondyloarthritis. Rheumatology, 2025, 64 (Supplement_3), ⟨10.1093/rheumatology/keaf142.329⟩. ⟨hal-05107335⟩

Collections

39 Consultations
0 Téléchargements

Altmetric

Partager

  • More